Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel

Journal of Pharmaceutical Sciences

Volumn 90, Issue 9, 2001, Pages 1324-1335

  Lovich, Mark A ^a,b   Creel, Chris ^a   Hong, Kristy ^a   Hwang, Chao Wei ^a   Edelman, Elazer R ^a,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Carrier protein mediated transport; Diffusion; Paclitaxel; Solubility; Vascular pharmacokinetics

Indexed keywords

CARRIER PROTEIN; PACLITAXEL;

ACTIVE TRANSPORT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BINDING SITE; CATTLE; CONTROLLED STUDY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; HYDROPHOBICITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; VASCULAR TISSUE;

EID: 0034834071     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.1085     Document Type: Article

References (45)

1. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle proliferation
2. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty
3. Suppression by heparin of smooth muscle cell proliferation in injured arteries
4. Kinetics of cellular proliferation after arterial injury. II: Inhibition of smooth muscle cell growth by heparin
5. Inhibition of rat arterial smooth muscle cell proliferation by heparin I. In vivo studies with anticoagulant and non-anticoagulant heparin
6. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty
7. Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation
8. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after injury
9. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Kinetics, distribution, and bioactivity of forskolin
10. Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions
11. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: Effects on restenosis and implications for catheter-based drug delivery
12. Inhibition of smooth muscle proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen
13. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle accumulation in vivo
14. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery
15. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat
16. Late effects of locally delivered mitomycin c on formation of neointima and on vasomotor response to acetylcholine
17. Interferon-gamma inhibits arterial stenosis after injury
18. Interstitial diffusion of macromolecules in the rat mesentary
19. Diffusion and convection in normal and neoplastic tissues
20. Transport of macromolecules in tumor microcirculation
21. Macromolecular transport in the cat mesentery
22. Computational simulations of local vascular heparin deposition and distribution
23. Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery
24. Tissue average binding and equilibrium distribution: An example with heparin in arterial tissues
25. Drug clearance and arterial uptake following local perivascular delivery to the rat carotid atery
26. Arterial heparin deposition: Role of diffusion, convection, and extravascular space
27. Drug delivery models transported to a new level
28. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis
29. Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug
30. Influence of blood components on the tissue uptake indices of cyclosporin in rats
31. Blood binding and tissue uptake of drugs. Recent advances and perspectives
32. Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding
33. 1 acid glycoprotein binding
34. Biopharmaceutics of paclitaxel (Taxol): Formulation, activity, and pharmacokinetics
35. Solid-state characterization of paclitaxel
36. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins
37. Arterial paclitaxel distribution and deposition
38. The distribution of labeled albumin across the rabbit thoracic aorta in vivo
39. Chemical composition and molecular parameters of purified plasma proteins
40. Binding of taxol to human plasma, albumin and alpha1-acid glycoprotein
41. Synthesis and evaluation of some water-soluble prodrugs and derivates of taxol with antitumor activity
42. A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs
43. Biologically active taxol analogues with a deleted A-ring side chain substituents and variable c-2′ configurations
44. Molecular weight distribution analysis by gel chromotography on sephadex